Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
37,885
Total Claims
$2.0M
Drug Cost
661
Beneficiaries
$2,995
Cost/Patient
Risk Score Breakdown 17/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+112%
Cost per patient vs peers
$2,995 vs $1,411 avg
+27%
Brand preference vs peers
13.5% vs 10.6% avg
Brand vs Generic
Brand: 5,116 claims · $1.3M
Generic: 32,708 claims · $680K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,226 | $288K |
| Rifaximin | 79 | $113K |
| Rivaroxaban | 371 | $87K |
| Sitagliptin Phosphate | 229 | $54K |
| Fluticasone/Umeclidin/Vilanter | 87 | $37K |
| Mirabegron | 174 | $35K |
| Memantine Hcl | 971 | $32K |
| Insulin Aspart | 115 | $30K |
| Pimavanserin Tartrate | 13 | $30K |
| Potassium Chloride | 1,151 | $30K |
| Insulin Aspart | 91 | $29K |
| Atorvastatin Calcium | 2,287 | $25K |
| Linagliptin | 84 | $24K |
| Darunavir/Cobicistat | 12 | $21K |
| Insulin Glargine,hum.Rec.Anlog | 92 | $21K |
Prescribing Profile
Patient Profile
82
Avg Age
66%
Female
2.64
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data